Analyst Price Target is GBX 433.33
▲ +9.37% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Oxford Biomedica in the last 3 months. The average price target is GBX 433.33, with a high forecast of GBX 740 and a low forecast of GBX 180. The average price target represents a 9.37% upside from the last price of GBX 396.21.
Current Consensus is
Hold
The current consensus among 3 investment analysts is to hold stock in Oxford Biomedica. This rating has held steady since September 2023, when it changed from a Moderate Buy consensus rating.
Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.
Read More